A Phase 2 Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2012
At a glance
- Drugs Cetuximab; PGG-glucan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Feb 2012 Actual patients number is 18 as reported by ClinicalTrials.gov.
- 14 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History